AbbVie Settles Legal Fight Against Amgen Over Humira Copycat

By Susan Decker and Cynthia Koons, Bloomberg News

AbbVie Inc. reached a deal with Amgen Inc. that will allow a copy of blockbuster arthritis drug Humira to be sold in Europe next year -- but a U.S. version won’t hit shelves until more than four years later.

Financial terms of the agreement weren’t disclosed. Amgen will pay AbbVie patent royalties when it begins sales of its drug, called Amgevita, in Europe on Oct. 16, 2018. The U.S. version, called Amjevita, will come to market on Jan. 31, 2023.

Settling with Amgen removes one possible legal threat for AbbVie, which gets ...